4.7 Article

Fluid-Attenuated Inversion Recovery Images and Stroke Outcome After Thrombolysis

期刊

STROKE
卷 43, 期 2, 页码 539-542

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.111.632026

关键词

acute stroke; magnetic resonance imaging; thrombolysis

资金

  1. Federal Ministry of Education and Research via from the Center for Stroke Research Berlin [01 EO 0801]
  2. Volkswagen Foundation
  3. EU (EuStroke, ARISE)
  4. German Research Foundation [SFB-TR 43]
  5. Astra Zeneca
  6. Bayer
  7. Berlin Chemie
  8. BMS
  9. Boehringer-Ingelheim
  10. Glaxo Smith Kline
  11. Novartis
  12. Pfizer
  13. Sanofi-Aventis
  14. Trommsdorff

向作者/读者索取更多资源

Background and Purpose-We investigated if hyperintensities on fluid-attenuated inversion recovery (FLAIR) sequences in arteries and parenchyma are associated with poor outcome 3 months after thrombolysis. Methods-Consecutive acute stroke patients with known time of symptom onset who had an MRI before and 1 day after thrombolysis were included in this study. Blinded to follow-up imaging and outcome, 2 raters independently judged the presence or absence of arterial and parenchymal FLAIR hyperintensities. Functional outcome (modified Rankin Scale) was assessed after 3 months. Results-Out of 90 patients, 22 had parenchymal FLAIR hyperintensities and 42 had hyperintense vessels. The combination of FLAIR hyperintensities in arteries and parenchyma occurred in 15 patients. Stepwise forward regression analysis revealed an adjusted odds ratio of 14.5 for a worse outcome (modified Rankin Scale score >2) in patients with FLAIR hyperintensities in arteries and parenchyma (95% confidence interval, 1.3-158.5; P=0.03). Conclusions-FLAIR hyperintensities in arteries and parenchyma are an easy-to-use MRI feature in acute ischemic stroke associated with poor outcome 3 months after thrombolysis. (Stroke. 2012;43:539-542.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据